The Institute for Clinical and Economic Review has tentatively concluded that four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients.

ICER Says Four Drugs Are Cost-Effective in Keeping COVID-19 Patients Out of Hospitals

The Institute for Clinical and Economic Review (ICER) has issued a draft report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients. The independent nonprofit group evaluates prescription drugs and medical treatments’ cost effectiveness and relative improvement to quality of life. The organization is highly respected by medical professionals, insurers, pharmacy buyers and government policy makers in helping to determine which drugs are cost-effective and are worth the value.

The drugs are sotrovimab, a monoclonal antibody manufactured by Glaxo SmithKline and marketed as Xevudy; the antiviral molnupiravir, manufactured by Merck; antiviral ritonavir, a Pfizer product used to treat HIV infection; and fluvoxamine, a generic selective serotonin reuptake inhibitor used primarily to treat obsessive compulsive.

The Institute for Clinical and Economic Review (ICER) has issued a draft report concluding four drugs have demonstrated effectiveness and value in reducing hospitalizations of COVID-19 patients.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer